Lupus & antiphospholipid syndrome
Associations of retention in care by visits or lupus-specific labs with acute care among young adults: A medicare cohort study
Main finding · Acute care use, adjustedResult — go to the resultAdjusted hazard ratio 0.79 95% CI 0.65–0.97Authors' conclusion
Receipt of complement or dsDNA antibody testing, a lupus-specific care quality indicator, was associated with reduced acute care use in young adults.
Study context
- Population
- Young adult (ages 18–35) Medicare beneficiaries with SLE28% had serologic testing
- Participants
- 1,036 participants
- Exposure
- Visit-based retention in rheumatology care or receipt of ≥1 complement or dsDNA test vs none
- Outcome
- Acute care use (ED visits and hospitalizations)
- Follow-up
- Subsequent 6 months
Methodological details20% national Medicare sample, Cox regression
- 20% national Medicare sample
- Cox regression
Main finding
Acute care use, adjusted · 6 months
Adjusted hazard ratio
0.79
95% CI 0.65–0.97
Serologic testingvs No serologic testing
aHR 0.79 (95% CI 0.65–0.97)
As reported in the abstract
- Acute care use at 6 months (overall)
- nearly 60%
Observational data: associations, not effects.
Further findings
Observed acute care-free survival time — Visit-based retention vs No visit-based retention
P = 0.02
| Outcome | P value |
|---|---|
| Observed acute care-free survival timeSerologic testing vs No serologic testing | P = 0.002 |
Original publication
Associations of retention in care by visits or lupus-specific labs with acute care among young adults: A medicare cohort study. Lupus. Published 18 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →